跳转至内容
Merck
CN
所有图片(1)

主要文件

安全信息

SML3279

Sigma-Aldrich

BC-2059

≥98% (HPLC)

别名:

BC 2059, BC2059, Tegatrabetan, Tegavivint, rel-2,7-Bis[[(3R,5S)-3,5-dimethyl-1-piperidinyl]sulfonyl]-9,10-anthracenedione 9,10-dioxime

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C28H36N4O6S2
分子量:
588.74
MDL编号:
UNSPSC代码:
12352200
NACRES:
NA.77

质量水平

方案

≥98% (HPLC)

表单

powder

颜色

white to beige

溶解性

DMSO: 2 mg/mL, clear

储存温度

−20°C

SMILES字符串

[S](=O)(=O)(N5C[C@H](C[C@H](C5)C)C)c1cc2c(cc1)C(c3c(cc(cc3)[S](=O)(=O)N4C[C@H](C[C@H](C4)C)C)C2N=O)N=O

InChI

1S/C28H36N4O6S2/c1-17-9-18(2)14-31(13-17)39(35,36)21-5-7-23-25(11-21)28(30-34)26-12-22(6-8-24(26)27(23)29-33)40(37,38)32-15-19(3)10-20(4)16-32/h5-8,11-12,17-20,27-28H,9-10,13-16H2,1-4H3/t17-,18+,19-,20+,27?,28?

InChI key

LQQUOMJXUXVPRB-IOTKHNBZSA-N

生化/生理作用

BC-2059 is a cell penetrant, potent and selective inhibitor of the Wnt-signaling pathway that potently inhibits growth of cancer cell lines in vitro. BC-2059 inhibits β-catenin/transducin β-like 1 (TBL1) complex by direct binding to TBL1 complexed with β-catenin. BC-2059 does not inhibit interaction of TBL1 with either NCoR/SMRT or NFkB. It is a potential therapeutic for tumors with deregulated Wnt signaling pathway.
cell penetrant, potent and selective inhibitor of the Wnt-signaling pathway; inhibitor of β-catenin/TBL1 complex

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

新产品

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Raffaella Soldi et al.
The Journal of pharmacology and experimental therapeutics, 378(2), 77-86 (2021-05-20)
The central role of β-catenin in the Wnt pathway makes it an attractive therapeutic target for cancers driven by aberrant Wnt signaling. We recently developed a small-molecule inhibitor, BC-2059, that promotes apoptosis by disrupting the β-catenin/transducin β-like 1 (TBL1) complex
Dyana T Saenz et al.
Leukemia, 33(6), 1373-1386 (2018-12-24)
Transformation of post-myeloproliferative neoplasms into secondary (s) AML exhibit poor clinical outcome. In addition to increased JAK-STAT and PI3K-AKT signaling, post-MPN sAML blast progenitor cells (BPCs) demonstrate increased nuclear β-catenin levels and TCF7L2 (TCF4) transcriptional activity. Knockdown of β-catenin or
Dyana T Saenz et al.
Blood, 135(15), 1255-1269 (2020-02-19)
The promising activity of BET protein inhibitors (BETi's) is compromised by adaptive or innate resistance in acute myeloid leukemia (AML). Here, modeling of BETi-persister/resistance (BETi-P/R) in human postmyeloproliferative neoplasm (post-MPN) secondary AML (sAML) cells demonstrated accessible and active chromatin in
Dyana T Saenz et al.
Leukemia, 33(6), 1373-1386 (2018-12-24)
Transformation of post-myeloproliferative neoplasms into secondary (s) AML exhibit poor clinical outcome. In addition to increased JAK-STAT and PI3K-AKT signaling, post-MPN sAML blast progenitor cells (BPCs) demonstrate increased nuclear β-catenin levels and TCF7L2 (TCF4) transcriptional activity. Knockdown of β-catenin or

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门